Finanzas de Resmed Inc (RMD)RMDResmed Inc

ResMed Inc. (RMD) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Devices, accounting for 51.4% of total sales, equivalent to $735.75M. Another important revenue stream is Masks and other. Understanding this composition is critical for investors evaluating how RMD navigates market cycles within the Advanced Medical Equipment & Technology industry.

Evaluating the bottom line, ResMed Inc. maintains a gross margin of 58.12%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 31.04%, while the net margin is 26.20%. These profitability ratios, combined with a Return on Equity (ROE) of 24.27%, provide a clear picture of how effectively RMD converts its operational activities into shareholder value.

In the context of the broader market, RMD competes directly with industry leaders such as MTD and DXCM. With a market capitalization of $31.90B, it holds a leading position in the sector. When comparing efficiency, RMD's gross margin of 58.12% stands against MTD's 61.40% and DXCM's 63.44%. Such benchmarking helps identify whether ResMed Inc. is trading at a premium or discount relative to its financial performance.

Resmed has shown consistent revenue growth, with Q4 2026 revenue reaching $1.46 billion, up from $1.28 billion in Q2 2025. The net income for Q4 2026 was $383.43 million, maintaining a strong net margin of 26.20%.